Key Points
- Major shareholder Chidozie Ugwumba sold 9,075 shares of Clene on Jan. 9 at an average price of $6.27 and has been disposing of shares across late Dec.–Jan., including a 32,705-share sale on Jan. 12.
- After these transactions Ugwumba still owns 741,292 shares (valued at about $4.65 million), with the recent trades reducing their position by roughly 1.21%.
- Clene’s stock is under pressure—recently down 18.9% and trading around $5.18 with a $53.5M market cap and negative earnings—yet analysts show a consensus "Moderate Buy" and an average price target of $32.60.
Clene Inc. (NASDAQ:CLNN - Get Free Report) major shareholder Chidozie Ugwumba sold 3,195 shares of the business's stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $6.09, for a total transaction of $19,457.55. Following the completion of the transaction, the insider owned 750,367 shares in the company, valued at $4,569,735.03. The trade was a 0.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.
Chidozie Ugwumba also recently made the following trade(s):
- On Monday, January 12th, Chidozie Ugwumba sold 32,705 shares of Clene stock. The shares were sold at an average price of $5.50, for a total transaction of $179,877.50.
- On Friday, January 9th, Chidozie Ugwumba sold 9,075 shares of Clene stock. The shares were sold at an average price of $6.27, for a total value of $56,900.25.
- On Wednesday, January 7th, Chidozie Ugwumba sold 3,938 shares of Clene stock. The stock was sold at an average price of $6.29, for a total value of $24,770.02.
- On Tuesday, January 6th, Chidozie Ugwumba sold 3,111 shares of Clene stock. The shares were sold at an average price of $6.04, for a total value of $18,790.44.
- On Monday, January 5th, Chidozie Ugwumba sold 5,869 shares of Clene stock. The shares were sold at an average price of $5.87, for a total value of $34,451.03.
- On Friday, January 2nd, Chidozie Ugwumba sold 4,015 shares of Clene stock. The stock was sold at an average price of $5.73, for a total value of $23,005.95.
- On Wednesday, December 31st, Chidozie Ugwumba sold 13,095 shares of Clene stock. The stock was sold at an average price of $5.81, for a total value of $76,081.95.
- On Tuesday, December 30th, Chidozie Ugwumba sold 4,138 shares of Clene stock. The shares were sold at an average price of $6.03, for a total transaction of $24,952.14.
- On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
- On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.
Clene Stock Performance
Clene stock opened at $5.18 on Tuesday. The company's 50 day simple moving average is $7.54 and its 200-day simple moving average is $6.45. Clene Inc. has a 1 year low of $2.28 and a 1 year high of $13.50. The company has a market capitalization of $53.51 million, a price-to-earnings ratio of -1.53 and a beta of 0.87.
Clene (NASDAQ:CLNN - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.06 million. Equities analysts expect that Clene Inc. will post -5.19 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on CLNN shares. UBS Group restated a "buy" rating on shares of Clene in a report on Wednesday, December 3rd. Weiss Ratings reissued a "sell (d-)" rating on shares of Clene in a research note on Friday. Benchmark restated a "buy" rating on shares of Clene in a report on Thursday, December 4th. Finally, D. Boral Capital reiterated a "buy" rating and set a $23.00 target price on shares of Clene in a report on Friday. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $32.60.
Check Out Our Latest Report on CLNN
Institutional Trading of Clene
A number of large investors have recently made changes to their positions in the company. Scoggin Management LP raised its holdings in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company's stock valued at $1,506,000 after acquiring an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. increased its position in shares of Clene by 2.5% in the 3rd quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company's stock valued at $315,000 after purchasing an additional 1,250 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Clene in the 2nd quarter valued at $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Clene in the 3rd quarter valued at $29,000. 23.28% of the stock is currently owned by hedge funds and other institutional investors.
Clene Company Profile
(
Get Free Report)
Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company's flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene's platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.
Clene's lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
